Key result
CPB initiation linked to a ~27% acute drop in methylprednisolone plasma concentrations.
Why the study?
Methylprednisolone pharmacokinetics and the influence of cardiopulmonary bypass on its plasma concentrations had not been comprehensively investigated in children with congenital heart disease.
What are the pharmacokinetics and plasma concentrations of methylprednisolone, and how does cardiopulmonary bypass influence them, in pediatric patients undergoing cardiac surgery?
Observational (n=36)
No
What are the pharmacokinetics and plasma concentrations of methylprednisolone, and how does cardiopulmonary bypass influence them, in pediatric patients undergoing cardiac surgery?
Initiation of cardiopulmonary bypass causes an acute, significant decrease in methylprednisolone plasma concentrations in pediatric patients, with large interindividual and age-dependent pharmacokinetic variability.
Answers are grounded in this paper and cite their sources.
May warrant PK-guided dosing adjustments at CPB onset in pediatric cardiac surgery; leaves open optimal regimens pending randomized trials.
Introduction:To our knowledge, methylprednisolone pharmacokinetics and plasma concentrations have not been comprehensively investigated in children with congenital heart disease undergoing cardiac surgery with cardiopulmonary bypass. It is unknown whether there is a significant influence of cardiopulmonary bypass on the plasma concentrations of methylprednisolone and whether this may be an explanation for the limited reported efficacy of steroid administration in cardiac surgery with cardiopulmonary bypass. Methods:The study was registered in the Dutch Trial Register (NTR3579; https://www.trialregister.nl/trial/3428 ). Methylprednisolone 30 mg/kg was administered as an intravenous bolus after induction of anesthesia. Methylprednisolone concentration was measured with liquid chromatography tandem mass spectrometry and analyzed using linear mixed-effects modeling. Results:Thirty-nine patients were included in the study, of which three were excluded. There was an acute decrease in observed methylprednisolone plasma concentration on initiation of cardiopulmonary bypass (median = 26.8%, range = 13.9–48.14%,p< 0.001). We found a lower intercept (p= 0.02), as well as a less steep slope of the model predicted methylprednisolone concentration vs. time curve for neonates (p= 0.048). A lower intercept (p= 0.01) and a less steep slope (p = 0.0024) if the volume of cell saver blood processed was larger than 91 ml/kg were also found. Discussion:We report similar methylprednisolone plasma concentrations as earlier studies performed in children undergoing cardiopulmonary bypass, and we confirmed the large interindividual variability in achieved methylprednisolone plasma concentrations with weight-based methylprednisolone administration. A larger volume of distribution and a lower clearance of methylprednisolone for neonates were suggested. The half-life of methylprednisolone in our study was calculated to be longer than 6 h for neonates, 4.7 h for infants, 3.6 h for preschool children and 4.7 h for school children. The possible influence of treatment of pulmonary hypertension with sildenafil and temperature needs to be investigated further.
No takes yet. Share an insight, caveat, or question.
Saet et al. (2021) conducted an observational in Congenital heart disease requiring cardiac surgery with cardiopulmonary bypass (n=36). Cardiopulmonary bypass vs. Pre-bypass baseline was evaluated on Acute decrease in observed methylprednisolone plasma concentration on initiation of cardiopulmonary bypass (26.8% median decrease, p=<0.001). Initiation of cardiopulmonary bypass resulted in a significant acute decrease in observed methylprednisolone plasma concentration by a median of 26.8%.
Synapse has enriched 10 related papers. Consider them for comparative context: